SRF and prostate carcinoma: A negative correlation was identified between SRF nuclear expression in bone metastases and survival from date of diagnosis with prostate cancer (Fig. 3a[i]; Spearman Rank Correlation −0.602, median difference in survival was 5.68 years), castration resistance (Fig. 3b[i]; Spearman Rank Correlation −0.813, median difference in survival was 2.89 years), and bone metastases (Fig. 3c[i]; Spearman Rank Correlation −0.672, median difference in survival was 3.6 years).